Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now LSE - Delayed Quote • GBp Oxford Biomedica plc (OXB.L) Follow Add holdings 295.00 0.00 (0.00%) At close: 5:29:44 PM GMT+1 All News Press Releases SEC Filings Oxford Biomedica Full Year 2024 Earnings: EPS Beats Expectations Oxford Biomedica ( LON:OXB ) Full Year 2024 Results Key Financial Results Revenue: UK£128.8m (up 44% from FY 2023). Net... Exploring Redcentric And 2 Other High Growth Tech Stocks In The UK The United Kingdom's market landscape has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines due to weak trade data from China, highlighting concerns over global economic recovery and its impact on UK companies. In this environment, identifying high-growth tech stocks like Redcentric becomes crucial as investors seek opportunities that can withstand external pressures and capitalize on technological advancements within the UK's evolving market. Oxford BioMedica PLC (OXBDF) (FY 2024) Earnings Call Highlights: Record Revenue Growth and ... Oxford BioMedica PLC (OXBDF) reports a 44% revenue increase and significant EBITDA improvement, while navigating market challenges and expanding its European footprint. When Will Oxford Biomedica plc (LON:OXB) Turn A Profit? We feel now is a pretty good time to analyse Oxford Biomedica plc's ( LON:OXB ) business as it appears the company may... Preliminary results for the year ended 31 December 2024 ~ Strong commercial momentum underpins transformative financial performance ~ Strong 2024 financial performance in line with guidance Revenue growth of 44% to £128.8 million compared to 2023, organic revenue growth of 81%1Operating EBITDA2 loss of £(15.3) million for the full year in line with expectations, Operating EBITDA profit of £5.0 million achieved in second half of 2024 Contracted value of client orders3 signed during 2024 reached approximately £186 million at 31 December 2024, an increa OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: OXB) (the "Company"), a quality and innovation-led cell and gene therapy CDMO, today announces that the Company has been recognised as a winner in the 'Cell & Gene Therapy – Global' category at the 2025 CDMO Leadership Awards. The annual CDMO Leadership Awards recognise excellence in contract development and manufacturing based on independent surveys from leading global bi OXB to present at the Leerink Partners Global Healthcare Conference OXB to present at the Leerink Partners Global Healthcare Conference Oxford, UK – 26 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that Dr. Lucinda Crabtree, Chief Financial Officer, will take part in a fireside chat at the Leerink Partners Global Healthcare Conference in Miami, Florida on Tuesday, 11 March 2025 at 2:20 PM EDT / 6:20 PM GMT. A live webcast of the fireside chat will be available on the ‘Investor Relations’ section of Boehringer and partners commence gene therapy trial for cystic fibrosis The Phase I/II trial will assess the therapy’s tolerability, efficacy and safety. High Growth Tech Stocks In The United Kingdom Featuring Beeks Financial Cloud Group The United Kingdom's stock market has been experiencing some turbulence, with the FTSE 100 closing lower due to weak trade data from China, highlighting the challenges faced by companies tied to global economic conditions. In this environment, identifying high-growth tech stocks can be particularly appealing as they often demonstrate resilience and potential for significant returns despite broader market uncertainties. OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis OXB’s lentiviral vector manufacturing technology to support Boehringer Ingelheim’s newly initiated Phase I/II trial of first-in-class gene therapy for cystic fibrosis Commencement of LENTICLAIR™ 1 trial, utilising OXB lentiviral vectors; builds on long term collaboration with Boehringer Ingelheim Oxford, UK – 20 February 2025: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces that its proprietary lentiviral vector manufacturing technology will be use Appointment of Joint Corporate Broker and Joint Financial Adviser Oxford, UK – 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint Corporate Broker and Joint Financial Adviser, to work alongside RBC Capital Markets, with immediate effect. -Ends- Enquiries: OXB: Sophia Bolhassan, Head of Investor Relations – T: +44 (0) 1865 509 737 / E: ir@oxb.com ICR Healthcare:T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com Mary-Jane Elliott / High Growth Tech Stocks In The United Kingdom January 2025 As the UK market grapples with the ripple effects of faltering trade data from China, reflected in the recent declines of both the FTSE 100 and FTSE 250 indices, investors are closely monitoring how these global economic challenges impact sectors reliant on international demand. In this environment, identifying high-growth tech stocks that demonstrate resilience through innovative solutions and robust business models becomes crucial for navigating potential market volatility. High Growth Tech Stocks In The UK To Watch December 2024 The United Kingdom's market has recently experienced a downturn, with the FTSE 100 and FTSE 250 indices closing lower amid weak trade data from China, highlighting ongoing global economic challenges. In this environment, identifying high growth tech stocks that can navigate such volatility becomes crucial, as these companies often possess innovative solutions and robust business models that may offer resilience against broader market pressures. Exploring High Growth Tech Stocks in the UK for November 2024 The United Kingdom's market has recently experienced a downturn, with the FTSE 100 closing lower due to weak trade data from China, highlighting concerns over global economic recovery and its impact on commodity-dependent sectors. In this challenging environment, identifying high-growth tech stocks in the UK requires focusing on companies that demonstrate resilience and innovation, as they are better positioned to navigate economic uncertainties and capitalize on emerging opportunities. OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development Oxford, UK – 20 November 2024: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces it will host a free 60-minute webinar exploring how advanced robotics can be used to speed up the development of viral vector drug products. The webinar titled "Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Re High Growth Tech Stocks In The UK October 2024 In the last week, the United Kingdom market has remained flat, although it has experienced a 12% increase over the past year, with earnings expected to grow by 14% annually. In this context of steady growth and positive forecasts, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and adaptability to capitalize on emerging opportunities within this dynamic sector. Exploring Three High Growth Tech Stocks in the United Kingdom In the current UK market landscape, the FTSE 100 has recently experienced declines due to weak trade data from China, highlighting global economic interdependencies and their impact on local indices. As investors navigate these challenges, identifying high-growth tech stocks in the United Kingdom requires a focus on companies that demonstrate resilience and innovation amidst broader market volatility. High Growth Tech Stocks In The UK Featuring Keywords Studios And Two More The UK market has faced challenges recently, with the FTSE 100 index experiencing a decline following weak trade data from China, highlighting concerns over global economic recovery and its impact on commodity-linked companies. In this environment, high-growth tech stocks such as Keywords Studios offer potential opportunities for investors seeking resilience and innovation amidst broader market uncertainties. High Growth Tech Stocks in the UK for October 2024 Over the past 7 days, the United Kingdom market has experienced a drop of 1.4%, yet it has risen by 12% over the last year, with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves looking for companies that demonstrate strong potential for innovation and scalability in line with these positive market trends. Exploring GB Group And 2 Other High Growth Tech Stocks In The UK Over the last 7 days, the United Kingdom market has remained flat, yet it is up 11% over the past year with earnings forecast to grow by 14% annually. In this context, identifying high growth tech stocks like GB Group involves looking for companies that demonstrate strong potential for expansion and innovation in a stable yet promising market environment. Performance Overview Trailing total returns as of 5/2/2025, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) Return OXB.L FTSE 100 (^FTSE) YTD -29.76% +5.18% 1-Year -1.67% +5.19% 3-Year -48.25% +13.94%